Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsPsyence Group2024-12-24T09:24:57+02:00December 23, 2024|Read More
Psyence Biomed Announces $2.0 Million Private PlacementPsyence Group2024-12-24T09:36:59+02:00December 23, 2024|Read More
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialPsyence Group2024-12-18T15:27:16+02:00December 18, 2024|Read More
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.Psyence Group2024-12-11T08:21:44+02:00December 11, 2024|Read More
Psyence Biomedical Issues Shareholder Update Highlighting Recent ProgressPsyence Group2024-12-04T08:02:02+02:00December 3, 2024|Read More
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications HearingPsyence Group2024-11-21T09:17:10+02:00November 21, 2024|Read More
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from NasdaqPsyence Group2024-11-14T07:57:10+02:00November 14, 2024|Read More
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabsPsyence Group2024-11-04T07:54:00+02:00November 4, 2024|Read More
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CarePsyence Group2024-10-25T09:35:57+02:00October 25, 2024|Read More
